The Priority Review

Clinical trials Brief

AbbVie posts results of Phase 3b TRITON study of Bimatoprost SR in glaucoma

The trial enrolled 515 participants and completed primary data collection on August 8, 2025. It evaluated the duration of intraocular pressure-lowering effect and safety of as-needed Bimatoprost SR in participants with open-angle glaucoma or ocular hypertension not adequately managed with topical IOP-lowering medication.

Primary source

ClinicalTrials.gov results record, November 13, 2026

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Read the source: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation